Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

Jakob Louis Thomsen

Status: Completed

Conditions: Neuromuscular Blockade

Treatments: Drug: Neostigmine; Drug: Rocuronium; Drug: Mivacurium; Drug: Sugammadex; Device: Objective neuromuscular monitoring (acceleromyography); Drug: Succinylcholine; Drug: Cisatracurium

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02914119

JLT-NM4

Details and patient eligibility

About

Aim: To explore

• the frequency of use of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia
• the incidence of residual neuromuscular blockade, and
• the timing of reversal of the neuromuscular blockade at the end of anaesthesia.

We will collect data from 7 Danish anaesthesia departments, using data from the Anaesthesia Information Management System (AIMS).

Enrollment: 30,430 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients who received general anaesthesia with neuromuscular blockade in one of the 7 hospitals providing data for the study in the last 18 months up until the time of data collection

Trial design

30,430 participants in 1 patient group

Eligible patients

Description:

Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection. Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received.

Treatment:

Drug: Mivacurium

Drug: Sugammadex

Drug: Rocuronium

Device: Objective neuromuscular monitoring (acceleromyography)

Drug: Succinylcholine

Drug: Neostigmine

Drug: Cisatracurium